Cataract & Refractive

Latest News


CME Content


Professor Auffarth of Heidelberg University Eye Clinic reports on the results of his implantation of the LENTIS Mplus and explains how the lens works using a new unique optical principle.

Allergan Inc. expects its ketorolac tromethamine ophthalmic solution 0.45% (Acuvail) to be available in the United States in September. The preservative-free formulation of ketorolac, a nonsteroidal anti-inflammatory drug (NSAID), is indicated for the treatment of pain and inflammation after cataract surgery and received FDA approval at the end of July, the company announced.

Researchers in Cleveland have discovered the first gene associated with the formation of age-related cataracts. EphA2 encodes an enzyme that plays a role in the repair of proteins in the lens of the eye after they become damaged and clump together, according to the investigators.

The use of implantable collamer lenses (ICLs) to correct moderate to high myopia can offer predictable and stable results over a long period of time, according to a report published in the July issue of Archives of Ophthalmology.

Implementation of novel techniques to analyze the fluidic signature of phacoemulsification performed using different ultrasound modalities and phaco tips is providing important insights that will be helpful for improving the efficiency and safety of lens removal surgery.

New fluidics concept

Oertli has developed a new phaco tip, easyTip2.2mm, based on the design of the CO-MICS 2. It uses a new fluidics concept with a high vacuum setting and a wide infusion path, creating a strong axially directed flow.

The Food and Drug Administration (FDA) has warned that doctors promoting LASIK may not be informing consumers correctly about potential risks involved.

According to a report in the Journal of the American Medical Association patients taking tamsulosin for benign prostrate enlargement within 14 days of cataract surgery may have an increased risk of complications.

The cataract surgery technology landscape including pipeline products at varying development stages comes under scrutiny in a new report released this month.

Oculentis will present its presbyopia correcting LENTIS Mplus IOL at DOC 2009 in Nuremberg to an expert audience. It claims the lens features a completely new approach in multi-focal lens technology.

Visiogen is reporting significant progress in the development of the Synchrony IOL, including the completion of the US phase III study, the formation of Visiogen Europe GmbH and the commencement of commercialization in Europe.